{
    "clinical_study": {
        "@rank": "144856", 
        "brief_summary": {
            "textblock": "RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using\n      tamoxifen or LY353381 may fight breast cancer by blocking the use of estrogen.\n\n      PURPOSE: This randomized phase I trial is studying how well tamoxifen works on the\n      biomarkers of the tumor tissue, compared with LY353381, in treating women with newly\n      diagnosed breast cancer."
        }, 
        "brief_title": "Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer", 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine whether LY353381 hydrochloride or tamoxifen administered in the interval\n           between biopsy and re-excision alters the expression of tissue biomarkers relative to\n           placebo controls in postmenopausal women with newly diagnosed breast cancer.\n\n      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study.\n\n        -  Phase I: Patients are randomized to receive either oral LY353381 hydrochloride or oral\n           placebo daily.\n\n      Upon completion of phase I, all treatment centers begin phase II of the study.\n\n        -  Phase II: Patients are randomized to receive either oral tamoxifen or oral placebo\n           daily.\n\n      Treatment in both phases continues for 2-6 weeks (until scheduled lumpectomy or mastectomy)\n      in the absence of disease progression or unacceptable toxicity.\n\n      Patients are followed at 1 and 2 weeks after surgery.\n\n      PROJECTED ACCRUAL: A minimum of 120 patients (60 per treatment phase) will be accrued for\n      this study within 18 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed noninvasive or small invasive breast cancer\n\n               -  Low or intermediate grade (ductal carcinoma in situ, T1, or T2) OR\n\n               -  Estrogen and/or progesterone receptor positive\n\n               -  Largest mass no greater than 5 cm\n\n               -  Clustered microcalcifications as only abnormality allowed with no upper size\n                  limit\n\n               -  If no distinction between mass and microcalcifications, size as 1 lesion\n\n          -  Lumpectomy or mastectomy must be planned for 2-6 weeks from start of study\n\n          -  No evidence of metastases from any malignancy\n\n          -  Hormone receptor status:\n\n               -  Estrogen and progesterone receptor positive (unless low or intermediate grade\n                  tumor)\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Sex:\n\n          -  Female\n\n        Menopausal status:\n\n          -  Postmenopausal by one of the following:\n\n               -  Prior oophorectomy\n\n               -  Over age 50 with prior hysterectomy, ovaries remaining\n\n               -  Uterus and ovaries intact and no menstrual period for more than 3 months\n\n        Performance status:\n\n          -  Not specified\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Platelet count greater than 100,000/mm^3\n\n          -  Hemoglobin greater than 10 g/dL\n\n          -  Absolute granulocyte count greater than 1,000/mm^3\n\n        Hepatic:\n\n          -  Albumin greater than 3 g/dL\n\n          -  Bilirubin less than 1.5 mg/dL\n\n          -  AST less than 100 U/L\n\n          -  Alkaline phosphatase less than 200 U/L\n\n        Renal:\n\n          -  Creatinine less than 1.5 mg/dL\n\n        Cardiovascular:\n\n          -  No history of deep vein thrombosis\n\n        Pulmonary:\n\n          -  No prior pulmonary embolus\n\n        Other:\n\n          -  Not pregnant or nursing\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Not specified\n\n        Chemotherapy:\n\n          -  At least 1 year since prior chemotherapy\n\n        Endocrine therapy:\n\n          -  At least 1 year since prior aromatase inhibitors, antiestrogens, or LH\n             agonists/antagonists\n\n          -  No concurrent hormone replacement therapy or oral contraceptives (from time of\n             randomization)\n\n        Radiotherapy:\n\n          -  Not specified\n\n        Surgery:\n\n          -  See Disease Characteristics\n\n        Other:\n\n          -  No concurrent treatment for other malignancy"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "June 2, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00005886", 
            "org_study_id": "CDR0000067956", 
            "secondary_id": [
                "KUMC-7813-99", 
                "KUMC-HSC-7419-98", 
                "NCI-P00-0158"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "arzoxifene hydrochloride", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "tamoxifen citrate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tamoxifen"
        }, 
        "keyword": [
            "stage I breast cancer", 
            "stage II breast cancer", 
            "ductal breast carcinoma in situ", 
            "breast cancer in situ"
        ], 
        "lastchanged_date": "July 23, 2008", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/KUMC-7813-99"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294-3300"
                    }, 
                    "name": "University of Alabama at Birmingham Comprehensive Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095-1781"
                    }, 
                    "name": "Jonsson Comprehensive Cancer Center, UCLA"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palm Springs", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92262"
                    }, 
                    "name": "Comprehensive Cancer Centers of the Desert"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maywood", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60153"
                    }, 
                    "name": "Loyola University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66160-7357"
                    }, 
                    "name": "University of Kansas Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }, 
                    "name": "Cleveland Clinic Taussig Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210-1240"
                    }, 
                    "name": "Arthur G. James Cancer Hospital - Ohio State University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19107-5541"
                    }, 
                    "name": "Kimmel Cancer Center of Thomas Jefferson University - Philadelphia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75246"
                    }, 
                    "name": "U.S. Oncology Research Inc."
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase IB Randomized Study of an Antiestrogen in Women With Newly Diagnosed Breast Cancer", 
        "overall_official": {
            "affiliation": "University of Kansas", 
            "last_name": "Carol J. Fabian, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "PMID": "15328178", 
            "citation": "Fabian CJ, Kimler BF, Anderson J, Tawfik OW, Mayo MS, Burak WE Jr, O'Shaughnessy JA, Albain KS, Hyams DM, Budd GT, Ganz PA, Sauter ER, Beenken SW, Grizzle WE, Fruehauf JP, Arneson DW, Bacus JW, Lagios MD, Johnson KA, Browne D. Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator. Clin Cancer Res. 2004 Aug 15;10(16):5403-17."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00005886"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Kansas", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2000", 
        "study_design": "Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2008"
    }, 
    "geocoordinates": {
        "Arthur G. James Cancer Hospital - Ohio State University": "39.961 -82.999", 
        "Cleveland Clinic Taussig Cancer Center": "41.499 -81.695", 
        "Comprehensive Cancer Centers of the Desert": "33.83 -116.545", 
        "Jonsson Comprehensive Cancer Center, UCLA": "34.052 -118.244", 
        "Kimmel Cancer Center of Thomas Jefferson University - Philadelphia": "39.952 -75.164", 
        "Loyola University Medical Center": "41.879 -87.843", 
        "U.S. Oncology Research Inc.": "32.803 -96.77", 
        "University of Alabama at Birmingham Comprehensive Cancer Center": "33.521 -86.802", 
        "University of Kansas Medical Center": "39.114 -94.627"
    }
}